Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immutep Ltd ( (AU:IMM) ) has provided an update.
Immutep Limited reported a significant increase in its loss after tax for the financial year ending June 30, 2025, primarily due to a $19.9 million rise in research and development and intellectual property expenses, largely attributed to clinical trial costs. Despite a rise in other income and interest income, the company’s net tangible asset backing per ordinary security decreased, and no dividends were declared, indicating financial challenges amidst ongoing investments in its core research activities.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$0.98 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Limited operates in the biotechnology industry, focusing on the development of immunotherapy treatments. The company is primarily engaged in research and development activities, particularly in the area of clinical trials for new therapies.
Average Trading Volume: 2,719,903
Technical Sentiment Signal: Sell
Current Market Cap: A$367M
See more insights into IMM stock on TipRanks’ Stock Analysis page.